Search bioRxiv⌕ Search

Biology subjects

Rajsfus, B. F.

Publications and source records attributed to Rajsfus, B. F..

2 recordsLinked to original sources

Interplay between Hyperglycemia and Chikungunya Virus Infection: Pathophysiological Insights from Murine Model

Chikungunya fever (CHIKF) is a re-emerging viral disease characterized by acute systemic manifestations and debilitating musculoskeletal symptoms that can persist after viral clearance. Although typically self-limiting in healthy individuals, clinical outcomes are significantly worsened in patients with pre-existing comorbidities, particularly diabetes mellitus (DM). Epidemiological data links DM to heightened CHIKF severity and a greater risk of developing chronic arthropathy, yet the mechanism underpinning this association remains poorly understood. In this study, we established an in vivo streptozotocin (STZ)-induced diabetic C57BL/6 mice as a model to investigate the impact of DM on CHIKV pathogenesis. STZ induces selective pancreatic {beta}-cell destruction and persistent hyperglycemia. Diabetic animals infected with CHIKV exhibited aggravated joint inflammation, increased nociceptive sensitivity, and elevated serum markers of muscle and hepatic injury, including creatine kinase (CK) and alanine aminotransferase (ALT). Histopathological analyses revealed that CHIKV infection alone disrupted joint architecture. However, in the diabetic context, these alterations were significantly exacerbated, with enhanced inflammatory infiltrates, chondrocyte loss, osteocyte necrosis, and fibrotic remodeling. These results demonstrate that the diabetic metabolic environment profoundly amplifies CHIKV-induced tissue damage and impairs resolution of inflammation, offering a plausible mechanistic explanation for the poorest CHIKF outcomes observed in diabetic patients. Thus, this model provides a valuable platform for exploring the molecular drivers of CHIKF severity and chronicity, especially among DM patients, as well as for development of pharmacological tools to mitigate CHIKV-associated complications in metabolically vulnerable populations. ImportanceChikungunya virus is responsible for a re-emerging disease that causes intense joint pain and long-lasting inflammation, especially in vulnerable individuals. People with diabetes are known to suffer more severe and persistent symptoms, but the biological reasons behind this have remained unclear. In this study, we used a diabetic mouse model to investigate how a high-glucose environment influences the course of Chikungunya virus infection. We found that diabetic mice experienced more intense joint damage, increased pain sensitivity, and signs of broader organ injury compared to non-diabetic animals. Microscopic analyses of tissues showed greater inflammation and structural damage in the joints of diabetic animals. These findings suggest that diabetes directly worsens the effects of Chikungunya virus infection by amplifying inflammation and delaying healing. This model helps explain why diabetic patients have worse outcomes and may assist in developing new treatments to protect high-risk populations from long-term complications of this infection.

immunology↗

The Escherichia coli TolC efflux pump protein is immunogenic and elicits protective antibodies

Antimicrobial resistance is an increasing worldwide public health burden that threatens to make the existent antimicrobials obsolete. Among the mechanisms of antimicrobial resistance is the overexpression of efflux pumps, such as the AcrA-AcrB-TolC which extrude diverse compounds, reducing the intracellular concentration of antimicrobials. TolC is the outer membrane protein of this pump and has recently gained attention as a therapeutic target. However, little is known about the immune response generated against the TolC protein. Here we evaluated the cellular and humoral immune response against the TolC from Escherichia coli. An in silico epitope prediction of the E. coli TolC showed several residues could bind to human antibodies, and we showed that human plasma presented anti-TolC IgG and IgA antibodies. Gram-negative infected patients presented a slight increase in anti-TolC IgM amounts, compared to controls. Recombinant E. coli TolC protein stimulated macrophages in vitro to produce nitric oxide, as well as IL-6 and TNF-, assessed by Griess assay and ELISA, respectively. Immunization of mice with TolC intraperitoneally and an in vitro re-stimulation of lymph node cells led to increased percentage of T cell proliferation and IFN{gamma} production, evaluated by flow cytometry and ELISA, respectively. We observed that TolC mouse immunization stimulated anti-TolC IgM and IgG production, with a higher level of IgG1 and IgG2, amongst the IgG subclasses. Finally, TolC IgG from mouse immune serum could bind to live E. coli, increase bacterial uptake by macrophages in vitro. TolC immunized mice had a survival rate increased in 60% post infection with E. coli. Our results showed that TolC is immunogenic, activating macrophages, T and B cells, leading to the production of protective antibodies against E. coli.

immunology↗